RIL
RXRX icon

Rothschild Investment LLC’s Recursion Pharmaceuticals RXRX Stock Holding History

Rothschild Investment LLC’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$936 Buy
255
+45
+21% +$150 ﹤0.01% 3072
2026
Q1 		$645 Buy
210
+70
+50% +$271 ﹤0.01% 3038
2025
Q4 		$573 Buy
140
+80
+133% +$396 ﹤0.01% 2886
2025
Q3 		$293 Sell
60
-540
-90% -$2.84K ﹤0.01% 2947
2025
Q2 		$3.04K Sell
600
-125
-17% -$614 ﹤0.01% 1780
2025
Q1 		$3.83K Buy
725
+350
+93% +$2.55K ﹤0.01% 1567
2024
Q4 		$2.54K Buy
375
+220
+142% +$1.48K ﹤0.01% 1658
2024
Q3 		$1.02K Buy
155
+80
+107% +$573 ﹤0.01% 2153
2024
Q2 		$563 Buy
75
+65
+650% +$567 ﹤0.01% 1936
2024
Q1 		$100 Buy
+10
New +$111 ﹤0.01% 2213

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Rothschild Investment LLC's RXRX Position: Q2 2026 in Review

Rothschild Investment LLC increased its Recursion Pharmaceuticals (RXRX) stake by 21% in Q2 2026, buying an estimated $150 and bringing the position to 255 shares worth $936. The position accounts for ﹤0.01% of the portfolio, ranked #3072.

Rothschild Investment LLC first reported a position in RXRX in Q1 2024 and has held it in 10 quarters since. The position peaked at $3.83K in Q1 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Rothschild Investment LLC held 255 shares of Recursion Pharmaceuticals worth $936 as of Q2 2026.
  • Rothschild Investment LLC bought 45 Recursion Pharmaceuticals shares in Q2 2026, an estimated $150.
  • Recursion Pharmaceuticals made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #3072 holding.
  • Rothschild Investment LLC first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Rothschild Investment LLC's Recursion Pharmaceuticals position peaked at $3.83K in Q1 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.